Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the safety and efficacy of novel autologous
CAR-T cells in patients with relapsed/refractory hematological malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
The Affiliated People's Hospital of Ningbo University